FCGR3A and breast cancer: Previously, Varchetta et al. found that trastuzumab therapy caused ADCC of NK and NKT cells in 15 of 18 patients with breast cancer overexpressing Her2, and the killing capacity of CD16+ lymphocytes depended on 158 V/F polymorphism of CD16A (49).